|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements:proposal for a new dosing regimen显示文摘 | Sconce EA Khan IT King BP | 2005 | Blood2005，106，7： | 1 |
| 2 | Pharmacogenetics of oral anticoagulants显示文摘 | King BP | 2003 | Pharmacogenetics2003，13，5： | 1 |
| 3 | Contribution of age,body size,and CYP2C9 genotype to anticoagulant response to warfarin显示文摘 | Kamali F Khan TI King BP Frearson R Kesteven P Wood P | 2004 | Clin Pharmacol Ther2004，75，： | 1 |
| 4 | Contribution of age,boby size, and CYP2C9 genotype to anticoagulant response to warfarin显示文摘 | Kamali F Khan TI King BP | 2004 | Clin Pharmacol Ther2004，75，3： | 1 |
| 5 | Contribution of age, body size, andCYP2C9 genotype to anticoagulant response to warfarin显示文摘 | Kamali F Khan TI King BP | 2004 | Clin PhamacolTher2004，75，： | 1 |
| 6 | Contribution of age,body size, and CYP2C9 genotype to anticoagulant response to warfarin 显示文摘 | Kamali F Khan TI King BP | 2004 | Clin Pharmacol Ther2004，75，3： | 1 |
| 7 | Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin 显示文摘 | Kamali F Khan TI King BP | 2004 | Clin Pharmacol Ther2004，75，： | 1 |
| 8 | The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements:proposal for a new dosing regimen显示文摘 | Sconce EA Khan TI Wynne HA Avery P Monkhouse L King BP | 2005 | Blood2005，106，： | 1 |
| 9 | Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin显示文摘 | Kamali F Khan TI King BP | 2004 | Clin Pharmacol Ther2004，75，3： | 1 |
| 10 | Rapid translation of circulating tumor cell biomarkers into clinical practice:technology development, ctmlcm needs and regulatory requirements 显示文摘 | King JD Casavant BP Lang JM | 2014 | Lab on a Chip2014，14，： | 1 |
| 11 | Range of motion and function are not affected by increased post constraint in patients undergoing posterior stabilized total knee arthroplasty显示文摘 | King BR Gladnick BP Lee YY | 2014 | Knee2014，21，1： | 1 |
| 12 | Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism 显示文摘 | King BP Khan TI Aithal GP Kamali F Daly AK | 2004 | Pharmoogenetics2004，14，： | 1 |
| 13 | The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen 显示文摘 | Sconce EA Khan TI Wynne HA Avery P Monkhouse L King BP | 2005 | Blood2005，106，7： | 1 |
| 14 | Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin显示文摘 | Kamali F Khan TI King BP | 2004 | Clin Pharma- col Ther2004，75，3： | 1 |
| 15 | Identification of a central phosphorylation site in p21-activated kinase regulating autoinhibition and kinase activity显示文摘 | Zenke FT King CC Bohl BP Bokoch GM | 1999 | J Biol Chem1999，274，32： | 1 |
| 16 | p21-activated kinase(PAK1)is phosphorylated and activated by3-phosphoinositide-dependent kinase-1(PDK1)显示文摘 | King CC Gardiner EM Zenke FT Bohl BP Newton AC Hemmings BA | 2000 | J Biol Chem2000，275，41： | 1 |
| 17 | Rapid translation of circulating tumor cell biomarkers into clinical practice:technology development,clinical needs and regulatory requirements显示文摘 | King JD Casavant BP Lang JM | 2014 | Lab Chip2014，14，1： | 1 |
| 18 | Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin 显示文摘 | Kamali F Khan TI King BP | 2004 | Clin Pharmacol Ther2004，75，3： | 1 |
| 19 | Rapid translation of circulating tumor cell biomarkers into clinical practice:technology development,clinical needs and regulatory requirements显示文摘 | King JD Casavant BP Lang JM | 2014 | Lab on a chip2014，14，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员